Clinical trial
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
NCT03365791
Study timeline
Study start (actual)2018-01-24Date precision: day
Registry last updated2022-05-27
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Small Cell Lung Cancerunresolved
Gastric Adenocarcinomaunresolved
Esophageal Adenocarcinomaunresolved
Soft Tissue Sarcomaunresolved
Ovarian Adenocarcinomaunresolved
Diffuse Large B Cell Lymphomaunresolved
Interventions
Sponsors & collaborators
Novartis Pharmaceuticalslead sponsor
Mapped research locations
HoustonTexas, United States2ChicagoIllinois, United States2BaltimoreMaryland, United States1San FranciscoCalifornia, United States1PortlandOregon, United States1IndianapolisIndiana, United States1OmahaNebraska, United States1Las VegasNevada, United States1MilwaukeeWisconsin, United States1MadisonWisconsin, United States1Iowa CityIowa, United States1PeoriaIllinois, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03365791 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.